The study, which began in North America in January, 2008 is evaluating the antiplatelet medicine CGT-2168, a combination of clopidogrel (currently marketed by Bristol-Myers Squibb and Sanofi-Aventis as Plavix) and a gastroprotectant (omeprazole) in a single pill.
Developed by Cogentus, CGT-2168 is designed to provide cardiovascular benefits while reducing potentially serious gastrointestinal side effects commonly associated with dual antiplatelet therapy.
Mark Goldsmith, Cogentus chairman and CEO, said: “Cogent has been very well received by the medical community in North America, with strong enrollment. Now we will begin to gather important data from investigators in Europe and broaden the patient base of the study.”